Is suvorexant (Belsomra) more effective and safer than zolpidem for elderly patients (≥65 years)?

Suvorexant (Belsomra) May Be Preferable to Zolpidem for Elderly Patients with Insomnia

For elderly patients (≥65 years) with chronic insomnia, suvorexant (Belsomra) appears to be the safer choice compared to zolpidem, primarily due to its superior safety profile regarding falls, balance impairment, and next-morning residual effects, despite both medications having similar weak recommendations in clinical guidelines.

Guideline Recommendations: Both Are Weakly Recommended

The 2017 American Academy of Sleep Medicine (AASM) guideline provides weak recommendations for both medications in adults with chronic insomnia 1:

• Suvorexant: Suggested for sleep maintenance insomnia (10,15/20, and 20 mg doses)
• Zolpidem: Suggested for both sleep onset and sleep maintenance insomnia (10 mg doses)

Importantly, both recommendations are classified as "weak," meaning clinicians must use clinical judgment and consider individual patient factors 1. The guideline does not make specific age-based distinctions, but this is where safety data becomes critical for elderly patients.

Efficacy: Comparable but Different Profiles

Sleep Maintenance (Primary Concern in Elderly)

Both medications improve sleep maintenance, but with different magnitudes 1:

• Suvorexant: Reduces wake after sleep onset by 16-28 minutes vs. placebo
• Zolpidem: Reduces wake after sleep onset by 25 minutes vs. placebo

Sleep Onset

• Suvorexant: Minimal effect on sleep latency (10 min improvement)
• Zolpidem: More robust effect on sleep latency (11.65 min reduction objectively) 1

Clinical Pearl: If the elderly patient's primary complaint is difficulty falling asleep, zolpidem has stronger sleep onset data. However, if sleep maintenance is the issue (more common in elderly), both are reasonable from an efficacy standpoint.

Safety: The Critical Differentiator in Elderly Patients

Falls and Balance Impairment

This is where suvorexant demonstrates clear advantages:

Zolpidem's Fall Risk:

• Associated with increased fracture risk (adjusted OR 1.72,95% CI 1.37-2.16) 2
• Associated with major head injury or fracture requiring hospitalization (adjusted HR 1.67,95% CI 1.19-2.34) 2
• FDA has lowered recommended starting dose to 5 mg in elderly due to safety concerns 1
• Small but significant increases in amnesia, dizziness, and somnolence 1

Suvorexant's Balance Profile:

• At 1.5 hours post-dose, suvorexant 30 mg (supratherapeutic) showed less balance impairment than zolpidem 5 mg (recommended elderly dose) 3
• No treatment differences in body sway at 4 or 8 hours post-dose 3
• FDA labeling specifically notes elderly patients are at higher risk of falls but found no clinically meaningful differences in safety between elderly and younger patients at recommended doses 4

Next-Morning Residual Effects

Suvorexant demonstrates superior next-morning safety 5:

• In healthy elderly (ages 63-75), single low-dose administration showed minimal residual effects
• Body sway testing showed zolpidem performed significantly worse than suvorexant 5
• No remarkable changes in physical and cognitive functions the morning after suvorexant 5

Sleep Architecture

Suvorexant preserves more natural sleep physiology 6:

• EEG spectral density profile more closely approximates normal sleep than zolpidem
• Zolpidem reduces spectral density across theta and alpha bands during both NREM and REM sleep
• Suvorexant has no significant effects on spectral density during NREM sleep

Other Safety Considerations

Zolpidem-specific concerns:

• Associated with psychiatric adverse events and memory/driving impairment per FDA reviews 2
• Inconsistent data on mortality risk 2
• Associated with incident cancers in one observational study 2

Suvorexant-specific concerns:

• Primary adverse effect is somnolence (7% vs. 3% placebo) 2
• FDA warnings include complex behaviors (sleep driving), cognitive/behavioral changes, but serious adverse effects are rare 2
• Mechanism-related "dream-abnormality" events (nightmares, abnormal dreams, hallucinations) 7

Dosing Recommendations for Elderly

Suvorexant

• Start with 10 mg at bedtime (FDA-approved elderly dose is 15 mg, but 10 mg studied and effective) 4
• Can increase to 15 mg if needed and tolerated
• Maximum 20 mg (though 15 mg is recommended for elderly)

Zolpidem (if chosen)

• Must use 5 mg in elderly (FDA-mandated lower dose) 1
• Extended-release formulation: 6.25 mg (though evidence is minimal and inconclusive) 1

Clinical Decision Algorithm

Choose Suvorexant when:

1. Patient has history of falls or high fall risk
2. Sleep maintenance is the primary complaint
3. Patient needs to maintain morning function/activities
4. Concern about cognitive impairment or memory issues

Consider Zolpidem when: 5. Sleep onset is the predominant problem 6. Patient has failed suvorexant trial 7. Cost is prohibitive (zolpidem is generic) 8. Patient has severe hepatic impairment (suvorexant not studied) 4

Critical Caveats

• Both medications carry Schedule IV controlled substance designation 4
• Neither should be first-line; cognitive behavioral therapy for insomnia (CBT-I) remains the gold standard
• Avoid in patients with severe obstructive sleep apnea or severe COPD (suvorexant not studied in severe cases) 4
• Monitor for complex sleep behaviors with both medications
• Suvorexant contraindicated in narcolepsy (mechanism-based)
• Recent meta-analysis confirms DORAs (including suvorexant) are effective and generally safe in elderly, though lemborexant and suvorexant showed higher treatment-emergent adverse events than placebo 8

Bottom Line

Given the elderly population's heightened vulnerability to falls, cognitive impairment, and medication-related adverse events, suvorexant's superior safety profile regarding balance, next-morning residual effects, and preservation of natural sleep architecture makes it the preferable choice over zolpidem 4, 5, 3. The efficacy is comparable for sleep maintenance, and while zolpidem has stronger sleep onset data, the safety advantages of suvorexant outweigh this difference in the elderly population where morbidity from falls and fractures poses significant risk.